References
1. Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB. Improving
outcomes for patients with sickle cell disease in the United States:
Making the case for more resources, surveillance, and longitudinal data.JAMA Health Forum . 2021;2(10):e213467.
doi:doi:10.1001/jamahealthforum.2021.3467
2. Skinner MW, Soucie JM, McLaughlin K. The national haemophilia program
standards, evaluation and oversight systems in the United States of
America. Blood Transfus . Apr 2014;12 Suppl 3:e542-8.
doi:10.2450/2014.0019-14s
3. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle
cell disease: summary of the 2014 evidence-based report by expert panel
members. JAMA . Sep 10 2014;312(10):1033-48.
doi:10.1001/jama.2014.10517
4. Reeves SL, Tribble AC, Madden B, Freed GL, Dombkowski KJ. Antibiotic
Prophylaxis for Children With Sickle Cell Anemia. Pediatrics . Mar
2018;141(3)doi:10.1542/peds.2017-2182
5. Kanter J, Phillips S, Schlenz AM, et al. Transcranial Doppler
Screening in a Current Cohort of Children With Sickle Cell Anemia:
Results From the DISPLACE Study. J Pediatr Hematol Oncol . Nov 1
2021;43(8):e1062-e1068. doi:10.1097/MPH.0000000000002103
6. Heitzer AM, Longoria J, Okhomina V, et al. Hydroxyurea treatment and
neurocognitive functioning in sickle cell disease from school age to
young adulthood. Br J Haematol . Oct 2021;195(2):256-266.
doi:10.1111/bjh.17687
7. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by
transfusions in children with sickle cell anemia and abnormal results on
transcranial Doppler ultrasonography. New England Journal of
Medicine . 1998;339(1):5-11.
8. Lanzkron S, Carroll CP, Haywood C, Jr. Mortality rates and age at
death from sickle cell disease: U.S., 1979-2005. Public Health
Rep . Mar-Apr 2013;128(2):110-6. doi:10.1177/003335491312800206
9. Manley AF. Legislation and funding for sickle cell services,
1972-1982. Am J Pediatr Hematol Oncol . Spring 1984;6(1):67-71.
10. Kanter J, Smith WR, Desai PC, et al. Building access to care in
adult sickle cell disease: defining models of care, essential
components, and economic aspects. Blood Adv . Aug 25
2020;4(16):3804-3813. doi:10.1182/bloodadvances.2020001743
11. Dalkey N, Helmer O. An experimental application of the Delphi method
to the use of experts. Management Science . April 1963
1963;9(3):458-467.
12. Power-Hays A, Li S, Mensah A, Sobota A. Universal screening for
social determinants of health in pediatric sickle cell disease: A
quality-improvement initiative. Pediatr Blood Cancer . Jan
2020;67(1):e28006. doi:10.1002/pbc.28006
13. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology
2020 guidelines for sickle cell disease: prevention, diagnosis, and
treatment of cerebrovascular disease in children and adults. Blood
Adv . Apr 28 2020;4(8):1554-1588. doi:10.1182/bloodadvances.2019001142
14. Meier ER, Janson IA, Hampton K, et al. Adherence to Quality of Care
Indicators and Location of Sickle Cell Care Within Indiana. J
Community Health . Feb 2020;45(1):81-87. doi:10.1007/s10900-019-00721-x
15. Brandow AM, Carroll CP, Creary S, et al. American Society of
Hematology 2020 guidelines for sickle cell disease: management of acute
and chronic pain. Blood Adv . Jun 23 2020;4(12):2656-2701.
doi:10.1182/bloodadvances.2020001851
16. Bryant R, Porter JS, Sobota A, Association of Pediatric
Hematology/Oncology N, American Society of Pediatri Hematology O.
APHON/ASPHO Policy Statement for the Transition of Patients With Sickle
Cell Disease From Pediatric to Adult Health Care. J Pediatr Oncol
Nurs . Nov-Dec 2015;32(6):355-9. doi:10.1177/1043454215591954
17. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute
care utilization and rehospitalizations for sickle cell disease.JAMA . Apr 7 2010;303(13):1288-94. doi:10.1001/jama.2010.378
18. Kayle M, Docherty SL, Sloane R, et al. Transition to adult care in
sickle cell disease: A longitudinal study of clinical characteristics
and disease severity. Pediatr Blood Cancer . Jan
2019;66(1):e27463. doi:10.1002/pbc.27463
19. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology
2020 guidelines for sickle cell disease: transfusion support.Blood Adv . Jan 28 2020;4(2):327-355.
doi:10.1182/bloodadvances.2019001143
20. Kanter J, Liem RI, Bernaudin F, et al. American Society of
Hematology 2021 guidelines for sickle cell disease: stem cell
transplantation. Blood Adv . Sep 28 2021;5(18):3668-3689.
doi:10.1182/bloodadvances.2021004394C
21. Karsenty C, Tubman VN, Liu CJ, Fasipe T, Wyatt KEK. Regional
anesthesia for sickle cell disease vaso-occlusive crisis: a
single-center case series. Pediatr Blood Cancer . 2022;
22. Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison
of US Federal and Foundation Funding of Research for Sickle Cell Disease
and Cystic Fibrosis and Factors Associated With Research Productivity.JAMA Netw Open . Mar 2 2020;3(3):e201737.
doi:10.1001/jamanetworkopen.2020.1737
23. Karkoska K, Appiah-Kubi A, Rocker J, Stoffels G, Aygun B. Management
of vaso-occlusive episodes in the day hospital decreases admissions in
children with sickle cell disease. Br J Haematol . Sep
2019;186(6):855-860. doi:10.1111/bjh.16002
24. Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong PW.
Better outcomes for patients treated at hospitals that participate in
clinical trials. Arch Intern Med . Mar 24 2008;168(6):657-62.
doi:10.1001/archinternmed.2007.124
25. Soucie JM, Nuss R, Evatt B, et al. Mortality among males with
hemophilia: relations with source of medical care. The Hemophilia
Surveillance System Project Investigators. Blood . Jul 15
2000;96(2):437-42.
26. Marshall BC, Nelson EC. Accelerating implementation of biomedical
research advances: critical elements of a successful 10 year Cystic
Fibrosis Foundation healthcare delivery improvement initiative.BMJ Qual Saf . Apr 2014;23 Suppl 1:i95-i103.
doi:10.1136/bmjqs-2013-002790
27. Mogayzel PJ, Jr., Dunitz J, Marrow LC, Hazle LA. Improving chronic
care delivery and outcomes: the impact of the cystic fibrosis Care
Center Network. BMJ Qual Saf . Apr 2014;23 Suppl 1:i3-8.
doi:10.1136/bmjqs-2013-002363
28. Freed GL. A Missed Opportunity to Address a National Shame: The Case
of Sickle Cell Disease in the United States. JAMA Pediatr . Aug 1
2019;173(8):715-716. doi:10.1001/jamapediatrics.2019.1536
29. Power-Hays A, Dandoy CE, Lorts A, et al. US News & World Report and
quality metrics: Inclusion of sickle cell disease is a matter of equity.Pediatr Blood Cancer . Apr 20 2022:e29679. doi:10.1002/pbc.29679
30. Power-Hays A, McGann PT. When Actions Speak Louder Than Words -
Racism and Sickle Cell Disease. N Engl J Med . Nov 12
2020;383(20):1902-1903. doi:10.1056/NEJMp2022125
31. Brown LC, Hampton KC, Bloom EM, Lawson D, Cooper SH, Meier ER. No
child left behind: Building a comprehensive sickle cell disease care
oasis in the Lake County, Indiana care desert. Pediatr Blood
Cancer . Aug 2022;69(8):e29619. doi:10.1002/pbc.29619
TABLE 1 Essential elements of pediatric SCD centers